BR112022014889A2 - Composto de sulfonamida ou sulfinamida possuindo efeito de indução de degradação da proteína brd4 e uso farmacêutico do mesmo - Google Patents
Composto de sulfonamida ou sulfinamida possuindo efeito de indução de degradação da proteína brd4 e uso farmacêutico do mesmoInfo
- Publication number
- BR112022014889A2 BR112022014889A2 BR112022014889A BR112022014889A BR112022014889A2 BR 112022014889 A2 BR112022014889 A2 BR 112022014889A2 BR 112022014889 A BR112022014889 A BR 112022014889A BR 112022014889 A BR112022014889 A BR 112022014889A BR 112022014889 A2 BR112022014889 A2 BR 112022014889A2
- Authority
- BR
- Brazil
- Prior art keywords
- effect
- protein degradation
- sulfonamide
- pharmaceutical use
- brd4 protein
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 108091005625 BRD4 Proteins 0.000 title abstract 3
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 title abstract 3
- 230000017854 proteolysis Effects 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020019227 | 2020-02-06 | ||
| PCT/JP2021/004231 WO2021157684A1 (ja) | 2020-02-06 | 2021-02-05 | Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014889A2 true BR112022014889A2 (pt) | 2022-09-20 |
Family
ID=77199607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014889A BR112022014889A2 (pt) | 2020-02-06 | 2021-02-05 | Composto de sulfonamida ou sulfinamida possuindo efeito de indução de degradação da proteína brd4 e uso farmacêutico do mesmo |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US12102641B2 (https=) |
| EP (1) | EP4105220A4 (https=) |
| JP (3) | JP7419406B2 (https=) |
| KR (1) | KR20220139912A (https=) |
| CN (1) | CN115087658B (https=) |
| AR (1) | AR121275A1 (https=) |
| AU (1) | AU2021215623A1 (https=) |
| BR (1) | BR112022014889A2 (https=) |
| CA (1) | CA3168824C (https=) |
| IL (1) | IL295041A (https=) |
| MX (1) | MX2022009700A (https=) |
| TW (1) | TWI887352B (https=) |
| WO (1) | WO2021157684A1 (https=) |
| ZA (1) | ZA202209896B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7419406B2 (ja) | 2020-02-06 | 2024-01-22 | 田辺三菱製薬株式会社 | Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途 |
| JP2022123408A (ja) * | 2021-02-12 | 2022-08-24 | 株式会社三洋物産 | 遊技機 |
| JP2022123894A (ja) * | 2021-02-12 | 2022-08-25 | 株式会社三洋物産 | 遊技機 |
| JP2022123407A (ja) * | 2021-02-12 | 2022-08-24 | 株式会社三洋物産 | 遊技機 |
| JP2022123893A (ja) * | 2021-02-12 | 2022-08-25 | 株式会社三洋物産 | 遊技機 |
| JP7852736B2 (ja) * | 2022-10-28 | 2026-04-28 | 株式会社村田製作所 | 電子部品および電子部品の実装構造 |
| WO2024251876A1 (en) * | 2023-06-07 | 2024-12-12 | KRæFTENS BEKæMPELSE | PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS |
| CN118359621B (zh) * | 2024-04-16 | 2025-05-16 | 上海陶术生物科技股份有限公司 | 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体 |
| CN120865239B (zh) * | 2025-09-25 | 2025-12-12 | 深圳大学 | 基于苯并咪唑融合共价弹头的降解剂及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959361A (en) | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
| EP0638560A4 (en) | 1991-10-11 | 1995-03-29 | Yoshitomi Pharmaceutical | MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *. |
| WO1994006802A1 (fr) * | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| JP2801500B2 (ja) | 1993-07-02 | 1998-09-21 | 株式会社トクヤマ | Ｎ−アルコキシカルボニルアミノ酸の製造方法 |
| CN1109037C (zh) | 1996-09-13 | 2003-05-21 | 三菱制药株式会社 | 噻吩并－三唑并二氮杂䓬化合物及其医药用途 |
| WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN108727380A (zh) * | 2017-04-13 | 2018-11-02 | 中国科学院上海药物研究所 | 一种brd4抑制剂及其制备和应用 |
| CN109503618A (zh) * | 2017-09-14 | 2019-03-22 | 成都海创药业有限公司 | 一种brd4抑制剂 |
| EP3723757A4 (en) | 2017-12-14 | 2021-08-18 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULE TYPE DEGRADATION AGENTS RECRUITING DCAF15 |
| US11629152B2 (en) * | 2018-03-30 | 2023-04-18 | Kyowa Kirin Co., Ltd. | Compound with anticancer activity |
| EP3819305A4 (en) * | 2018-07-04 | 2022-04-06 | Mitsubishi Tanabe Pharma Corporation | AMIDE COMPOUND WITH BET PROTEOLYSIS-INDUCING ACTIVITY AND MEDICAL USE THEREOF |
| JP7140273B2 (ja) | 2019-04-09 | 2022-09-21 | 株式会社村田製作所 | 電池 |
| JP7419406B2 (ja) * | 2020-02-06 | 2024-01-22 | 田辺三菱製薬株式会社 | Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途 |
-
2021
- 2021-02-05 JP JP2021575876A patent/JP7419406B2/ja active Active
- 2021-02-05 MX MX2022009700A patent/MX2022009700A/es unknown
- 2021-02-05 CN CN202180012524.0A patent/CN115087658B/zh active Active
- 2021-02-05 TW TW110104483A patent/TWI887352B/zh active
- 2021-02-05 IL IL295041A patent/IL295041A/en unknown
- 2021-02-05 WO PCT/JP2021/004231 patent/WO2021157684A1/ja not_active Ceased
- 2021-02-05 AR ARP210100302A patent/AR121275A1/es unknown
- 2021-02-05 US US17/796,258 patent/US12102641B2/en active Active
- 2021-02-05 EP EP21750647.6A patent/EP4105220A4/en active Pending
- 2021-02-05 KR KR1020227030071A patent/KR20220139912A/ko active Pending
- 2021-02-05 BR BR112022014889A patent/BR112022014889A2/pt unknown
- 2021-02-05 AU AU2021215623A patent/AU2021215623A1/en active Pending
- 2021-02-05 CA CA3168824A patent/CA3168824C/en active Active
-
2022
- 2022-09-05 ZA ZA2022/09896A patent/ZA202209896B/en unknown
-
2023
- 2023-07-20 US US18/355,554 patent/US11890288B2/en active Active
-
2024
- 2024-01-10 JP JP2024001990A patent/JP7681737B2/ja active Active
- 2024-08-06 US US18/795,713 patent/US20240390387A1/en active Pending
-
2025
- 2025-05-12 JP JP2025079628A patent/JP2025122015A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220139912A (ko) | 2022-10-17 |
| US20230146717A1 (en) | 2023-05-11 |
| TWI887352B (zh) | 2025-06-21 |
| ZA202209896B (en) | 2025-12-17 |
| MX2022009700A (es) | 2022-09-07 |
| US12102641B2 (en) | 2024-10-01 |
| WO2021157684A1 (ja) | 2021-08-12 |
| EP4105220A4 (en) | 2024-02-21 |
| IL295041A (en) | 2022-09-01 |
| AU2021215623A1 (en) | 2022-08-25 |
| CA3168824C (en) | 2024-10-22 |
| TW202140498A (zh) | 2021-11-01 |
| US20230364105A1 (en) | 2023-11-16 |
| AR121275A1 (es) | 2022-05-04 |
| CN115087658B (zh) | 2025-02-28 |
| JPWO2021157684A1 (https=) | 2021-08-12 |
| JP2024041888A (ja) | 2024-03-27 |
| JP7419406B2 (ja) | 2024-01-22 |
| CA3168824A1 (en) | 2021-08-12 |
| EP4105220A1 (en) | 2022-12-21 |
| JP2025122015A (ja) | 2025-08-20 |
| CN115087658A (zh) | 2022-09-20 |
| US11890288B2 (en) | 2024-02-06 |
| JP7681737B2 (ja) | 2025-05-22 |
| US20240390387A1 (en) | 2024-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014889A2 (pt) | Composto de sulfonamida ou sulfinamida possuindo efeito de indução de degradação da proteína brd4 e uso farmacêutico do mesmo | |
| BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
| BR112015020302A2 (pt) | derivado de pirazol | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| BR112021025810A2 (pt) | Compostos radiomarcados direcionando o antígeno de membrana específico da próstata | |
| BR112022010323A2 (pt) | Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112017018872A2 (pt) | combinação de um antagonista pd-1 e eribulina para tratamento de câncer | |
| BR112015029144A2 (pt) | formulações de gel para guiar radioterapia | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
| BR112012031580A2 (pt) | derivado de tetra-hidrocarbolina | |
| BRPI0706992C1 (pt) | composto de fórmula (i) e formulação farmacêutica | |
| BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
| BR112018011700A2 (pt) | ?moduladores de canais de kv3 para tratar dor? | |
| BR112015022092A8 (pt) | derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo | |
| CO2020004669A2 (es) | Derivados de bencimidazol y sus usos | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112015022385A2 (pt) | droga para uma doença respiratória | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| BR112018076800A2 (pt) | derivado de guanidina, medicamento, inibidor da proteína 1 da translocação de linfoma de tecido linfóide associado com mucosa, e, agente terapêutico ou profilático. | |
| BR112022022005A2 (pt) | Derivado de 3-azabiciclo(3.1.0)hexano tendo atividade inibidora da kdm5 e uso do mesmo | |
| BR112022008457A2 (pt) | Agente terapêutico e agente profilático para distúrbios gastrointestinais funcionais e xerostomia |